# Drug of interest
My drug of interest is quinine.

# Pre-ranked list of genes
These are the candidate genes for this drugs, tentatively ranked by the likelihood of a pharmacogenetic relationship:
1. CYP2D6 (z: 27.38)
2. CYP2D7 (z: 5.4)
3. CYP3A5 (z: 2.11)
4. CYP3A4 (z: 2.04)
5. G6PD (z: 1.58)
6. KCNH2 (z: 1.45)
7. KCNE1 (z: 1.44)
8. ABCB1 (z: 1.18)
9. CYP2C19 (z: 1.11)
10. CYP2S1 (z: 1.05)
11. CYP2A13 (z: 0.51)
12. CYP3A7 (z: 0.42)
13. CYP1A2 (z: 0.41)
14. CYP2C9 (z: 0.4)
15. CYP2F1 (z: 0.38)
16. FMO5 (z: 0.38)
17. FMO4 (z: 0.35)
18. CYP2B6 (z: 0.32)
19. CYP2A7 (z: 0.3)
20. CYP2C18 (z: 0.3)
21. CYP3A43 (z: 0.29)
22. SLC22A1 (z: 0.28)
23. CYP2J2 (z: 0.28)
24. CYP2E1 (z: 0.25)
25. SLC22A7 (z: 0.16)
26. CYP2C8 (z: 0.15)
27. CYP21A2 (z: 0.14)
28. ABCB4 (z: 0.14)
29. KCNIP1 (z: 0.1)
30. SLC2A4 (z: 0.07)
31. SIK3 (z: 0.07)
32. KCNQ1 (z: 0.07)
33. UGT2B7 (z: 0.06)
34. CYP4F11 (z: 0.06)
35. CACNA1C (z: 0.06)
36. NOS1AP (z: 0.05)
37. CYP4B1 (z: 0.05)
38. CYP2A6 (z: 0.05)
39. IGF2-AS (z: 0.05)
40. XRCC5 (z: 0.04)
41. CYP4X1 (z: 0.03)
42. CYP4F12 (z: 0.02)
43. KCNMA1 (z: 0.02)
44. CYP4A11 (z: 0.01)
45. CYP4F3 (z: 0.0)
46. CYP1B1 (z: -0.0)
47. CACNB2 (z: -0.01)
48. SCN5A (z: -0.02)
49. CYP4F8 (z: -0.03)
50. KCNIP4 (z: -0.03)

# Auxiliary information about the drug
Below is some auxiliary information about the drug of interest:

**quinine**: Genetic polymorphisms in metabolic enzymes, primarily CYP3A4 and CYP3A5, and transport proteins like SLC22A1 and ABCB1, significantly influence the clearance, distribution, and excretion of quinine, leading to variability in its efficacy and safety profiles. Additional variations in genes like CYP2D6 and pathological conditions like G6PD deficiency can modify quinine's pharmacokinetics and induce adverse effects like hemolytic anemia in susceptible individuals.

# Auxiliary information about the genes
Below is some auxiliary information about the genes in the pre-ranked list:
**CYP2D6**: CYP2D6 enzyme is crucial in metabolizing drugs, including codeine, antidepressants like paroxetine and fluoxetine, the antipsychotic risperidone, tamoxifen, and beta-blockers such as metoprolol and timolol, with genetic variations influencing their plasma levels and effects. Differences in CYP2D6 activity can lead to different therapeutic outcomes, with poor metabolizers experiencing potential toxicity and ultrarapid metabolizers having reduced drug efficacy, making pharmacogenetic knowledge essential for adjusting dosages or choosing alternative therapies to optimize treatment efficacy and safety.

**CYP2D7**: CYP2D7, a pseudogene, does not encode a functional enzyme and thus does not partake in the metabolism of drugs, unlike its close relative CYP2D6, which metabolizes about 25% of clinically used drugs such as antidepressants, antipsychotics, beta-blockers, and opioids. Although CYP2D7 does not directly interact with these drugs, its similarity to CYP2D6 makes its study important for ensuring accurate pharmacogenetic testing and understanding genetic misannotations which can affect drug dosing and therapy.

**CYP3A5**: CYP3A5 plays a key role in the metabolism of several drugs, including immunosuppressants like tacrolimus and cyclosporine, where genetic variants impact dosing due to altered metabolism rates. This enzyme also affects the metabolism and effectiveness of other drugs such as itraconazole, statins (simvastatin and atorvastatin), apixaban, vincristine, ondansetron, atazanavir, and fentanyl, which in turn influences their therapeutic outcomes and risk profiles.

**CYP3A4**: CYP3A4, significantly expressed in the liver and small intestine, influences the metabolism and thus the effects and toxicity of many drugs, including tacrolimus, statins like atorvastatin and lovastatin, chemotherapeutics such as docetaxel, and sedatives like midazolam. Interaction with inducers or inhibitors like carbamazepine and erythromycin respectively can either increase or decrease CYP3A4's activity, affecting the metabolism of other drugs such as sildenafil and necessitating dosage adjustments due to changes in pharmacokinetic profiles.

**G6PD**: Certain medications exacerbate hemolysis in individuals with G6PD deficiency due to their effects on oxidative stress and redox balance within cells. Notably, antimalarials like primaquine and chloroquine, antibiotics such as dapsone, sulfasalazine, and sulfamethoxazole, NSAIDs including aspirin and ibuprofen, and potentially diabetic medications like gliclazide and glimepiride, as well as anticoagulants such as warfarin, can precipitate hemolytic reactions, necessitating careful management to avoid these drugs in affected individuals.

**KCNH2**: Various drugs, including sotalol, quinidine, amiodarone, disopyramide, fexofenadine, and nitrendipine, interact with the KCNH2 gene, which encodes the hERG channel involved in cardiac repolarization. These drugs block the IKr current mediated by the hERG channel, leading to potentially fatal prolonged QT intervals and increased risk of arrhythmias, with the severity of interaction and direct blocking effects differing among the drugs.

**KCNE1**: Drugs such as amiodarone, quinidine, and sotalol interact with the KCNE1 gene, which encodes a component of potassium channels involved in cardiac repolarization. These interactions significantly affect the QT interval on an electrocardiogram, particularly in patients with specific genetic variants of KCNE1, influencing the risk of developing severe arrhythmias like torsades de pointes.

**ABCB1**: The ABCB1 gene, encoding P-glycoprotein, is crucial in modulating the pharmacokinetics and efficacy of multiple drugs by acting as an efflux transporter that influences their absorption, distribution, and excretion. This gene affects the bioavailability and brain penetration of various drugs such as antivirals like efavirenz and ritonavir, chemotherapeutics like doxorubicin and paclitaxel, cardiovascular drugs like digoxin, immunosuppressants such as tacrolimus and sirolimus, and analgesics like morphine and codeine, necessitating dosage adjustments and careful monitoring in clinical practice for optimized therapeutic outcomes.

**CYP2C19**: The enzyme CYP2C19 significantly influences the metabolism of various drugs including clopidogrel, proton pump inhibitors (omeprazole, esomeprazole), antidepressants (citalopram, escitalopram), antiepileptics (phenytoin), antifungals (voriconazole), and analgesics (methadone, oxycodone), which impacts their therapeutic efficacy and safety. Variations in the CYP2C19 gene affect drug activation and metabolism, leading to different pharmacological outcomes and necessitating genotype-guided dosing to optimize treatment efficacy and minimize adverse effects.

**CYP2S1**: CYP2S1, a cytochrome P450 enzyme, influences the metabolism and efficacy of drugs, especially those administered via inhalation or topically, due to its expression in the liver, lungs, and skin. Although specific drugs affected by CYP2S1 are not well-determined, variations in the CYP2S1 gene can alter how these drugs are metabolized, potentially affecting their efficacy and toxicity.

**CYP2A13**: CYP2A13, a cytochrome P450 enzyme primarily found in the respiratory tract, plays a significant role in activating procarcinogens in tobacco smoke, such as nitrosamines, impacting lung cancer risk among smokers. Although it does not metabolize nicotine directly, CYP2A13 affects the activation of other smoke components that interact with nicotine's pathway, potentially influencing nicotine addiction and cancer risks, with genetic variations in CYP2A13 altering susceptibility to these effects.

**CYP3A7**: The CYP3A7 enzyme, important in fetal liver metabolism, interacts with drugs like atorvastatin and tacrolimus by potentially altering their pharmacokinetic profiles and systemic exposure during fetal development due to its activity in metabolizing these CYP3A substrates. Additionally, corticosteroids such as betamethasone and cortisone acetate may also interact with CYP3A7, affecting their metabolic rates and therapeutic outcomes in neonates and infants, though the specific pathway (pharmacokinetic or pharmacodynamic) of these interactions is less defined.

**CYP1A2**: CYP1A2 plays a pivotal role in the pharmacokinetics of drugs, influencing their metabolism and, consequently, efficacy and safety. This enzyme is responsible for processing medications such as clozapine, theophylline, caffeine, erlotinib, deferasirox, escitalopram, and clopidogrel, where genetic variability can significantly affect therapeutic outcomes and requires careful dosage adjustments to prevent toxicity or enhance drug effectiveness.

**CYP2C9**: CYP2C9 gene polymorphisms influence the metabolism of various drugs, affecting their therapeutic effectiveness and risk of side effects. Drugs such as warfarin, phenytoin, celecoxib, losartan, and tolbutamide require dose customization based on CYP2C9 genetic variants to optimize treatment outcomes and minimize complications like bleeding, drug toxicity, and gastrointestinal issues.

**CYP2F1**: CYP2F1, involved mainly in metabolizing inhaled environmental pollutants like naphthalene, has limited direct interaction with common drugs but plays a role in the metabolism of certain pharmaceuticals such as imatinib due to shared metabolic pathways or competitive inhibition. Although CYP2F1 does not typically directly influence imatinib's metabolism, its interaction with similar chemical structures could alter the drug's efficacy or toxicity in individuals with specific gene variants.

**FMO5**: The FMO5 gene, unlike its family members, has a unique role in pharmacogenetics, particularly due to its broad substrate specificity and presence in the liver and small intestine. It indirectly influences drug metabolism, such as with metformin, by potentially altering the metabolic environment or modifying intermediate biomolecules, thus affecting the drug's efficacy and safety through non-traditional pathways related to its handling of metabolic byproducts connected to sulfur and nitrogen.

**FMO4**: The FMO4 gene encodes for the enzyme flavin-containing monooxygenase 4, which potentially contributes to the metabolism of drugs by affecting their pharmacokinetics, altering plasma drug levels, and impacting therapeutic outcomes or side effects. The exact drugs impacted by FMO4 are still speculative, as FMO4’s interactions with specific drugs are currently not well-documented and remain under research.

**CYP2B6**: CYP2B6 plays a pivotal role in the metabolism of several drugs, including efavirenz, nevirapine, methadone, bupropion, cyclophosphamide, and ifosfamide, where genetic polymorphisms can significantly influence drug efficacy and safety by altering pharmacokinetic profiles. Genetic variations in CYP2B6 affect the enzyme activity, leading to differences in drug plasma concentrations, therapeutic effects, and potential adverse reactions in individuals, underscoring its importance in personalized medicine.

**CYP2A7**: CYP2A7, a lesser-known member of the cytochrome P450 family, does not have well-established pharmacogenetic interactions with drugs like mercaptopurine, although it might theoretically affect mercaptopurine's metabolism similarly to its related isoform, CYP2A6. The interaction and impact of CYP2A7 on the metabolism of mercaptopurine are speculative and require further evidence, as mercaptopurine is primarily metabolized through other pathways involving TPMT and XO.

**CYP2C18**: CYP2C18 plays a modest role in the metabolism of drugs like warfarin, escitalopram, and clozapine, mainly affecting their clearance or efficacy to a lesser extent than more prominent CYP enzymes. Genetic variations in CYP2C18 could influence the pharmacodynamics of drugs such as clopidogrel and acenocoumarol, rather than their pharmacokinetic profiles, indicating a potential need for personalized medicine considerations despite the enzyme's relative minor role.

**CYP3A43**: The gene CYP3A43, although not a major player in drug metabolism compared to other enzymes in its subfamily, is known to have specific pharmacokinetic interactions with drugs like olanzapine and ticagrelor, influencing their clearance and plasma concentrations to a minor degree. Its interactions with other antipsychotic drugs such as quetiapine, haloperidol, aripiprazole, risperidone, and clozapine are less defined and are likely related to broader metabolic pathways or pharmacodynamic responses, where CYP3A43 plays a marginal role.

**SLC22A1**: The gene SLC22A1, encoding for the organic cation transporter 1 (OCT1), significantly influences the absorption and distribution of various drugs, such as metformin, tramadol, lamotrigine, ondansetron, rasagiline, and imatinib, by affecting their hepatic uptake. Genetic variations in SLC22A1 can lead to different efficacy and safety profiles for these drugs, necessitating potential dosage adjustments in the management of conditions like diabetes, pain, epilepsy, nausea, Parkinson’s disease, and chronic myeloid leukemia.

**CYP2J2**: CYP2J2, primarily involved in metabolizing polyunsaturated fatty acids affecting cardiovascular physiology, does not have well-documented direct pharmacokinetic interactions with drugs like mycophenolate mofetil and tacrolimus. However, its role in modulating vascular tone and inflammation could potentially influence the pharmacodynamics of these immunosuppressive drugs used in organ transplantation and autoimmune diseases, despite the lack of a direct metabolic pathway involving CYP2J2.

**CYP2E1**: The gene CYP2E1 significantly impacts the metabolism of various drugs; for instance, in the case of acetaminophen and isoniazid, variations in CYP2E1 activity can lead to differences in the rate at which these drugs are metabolized, thereby affecting their efficacy, toxicity, and risk of adverse effects such as hepatotoxicity. Additionally, CYP2E1 metabolizes other substances like caffeine, theophylline, nicotine, and some procarcinogens, indicating that genetic variations could influence both therapeutic outcomes and disease risk through pharmacokinetic and possibly pharmacodynamic interactions.

**SLC22A7**: Genetic variations in the SLC22A7 gene, which encodes for the Organic Anion Transporter 3 (OAT3), significantly affect the renal excretion and therefore the clearance, efficacy, and toxicity of various drugs such as cefotaxime, oseltamivir, doxorubicin, daunorubicin, and capecitabine. These interactions might influence not just the pharmacokinetics but also the therapeutic and toxic effects of these drugs due to the role of OAT3 in altering their availability at cellular or tissue levels.

**CYP2C8**: The CYP2C8 gene plays a crucial role in metabolizing various medications such as paclitaxel, pioglitazone, repaglinide, and amodiaquine, affecting their efficacy and toxicity due to genetic variations that influence drug metabolism and exposure. These interactions, involving pharmacokinetic processes, suggest that CYP2C8 genetic testing could be utilized to optimize drug dosing and reduce toxicity.

**CYP21A2**: The pharmacogenetic interactions of CYP21A2 focus on its role in managing congenital adrenal hyperplasia (CAH), where mutations in this gene affect enzyme activity crucial for steroid biosynthesis. This dictates the use of tailored glucocorticoid therapy, using drugs like hydrocortisone in children and prednisone or dexamethasone in adults, and fludrocortisone for aldosterone deficiency. Treatment adjustments—including the choice and dosage of medication—are essential based on specific CYP21A2 mutations to avoid negative effects such as growth suppression or insufficient control of androgen excess.

**ABCB4**: ABCB4 mutations, which alter the function of the MDR3 protein, can impact the pharmacokinetics of the drug imatinib, used for treating chronic myeloid leukemia, by affecting the drug's transport and disposition in hepatocytes. This interaction may change the drug’s effectiveness and increase the risk of drug-induced liver injury (DILI), highlighting the potential importance of considering ABCB4 gene variations in personalized dosing or therapy for optimal treatment outcomes and reduced liver complication risks.

**KCNIP1**: The gene KCNIP1, which modulates A-type potassium channels and affects calcium channel activity, could potentially interact with drugs like verapamil, a calcium channel blocker used for treating cardiovascular conditions. This hypothetical interaction suggests that KCNIP1 might influence the pharmacodynamics of verapamil, affecting how calcium channels respond to the drug, potentially impacting its efficacy and variability in patient responses.

**SLC2A4**: The SLC2A4 gene (GLUT4) plays a crucial role in the pharmacogenetics of diabetes treatments such as metformin and thiazolidinediones (e.g., pioglitazone and rosiglitazone) by influencing insulin sensitivity and glucose uptake in cells. Variants in the SLC2A4 gene can alter GLUT4's expression or activity, thus impacting the effectiveness of these drugs in improving insulin sensitivity and glucose absorption, which focuses on pharmacodynamic interactions relevant to personalized diabetic treatment strategies.

**SIK3**: Variations in the SIK3 gene, which plays a role in lipid and glucose metabolism through the AMPK signaling pathway, may impact the effectiveness of metabolic disorder drugs like metformin, which activates AMPK. These genetic variations potentially affect the pharmacodynamics of such drugs, influencing their efficacy in treating conditions like type 2 diabetes and obesity based on individual genetic differences.

**KCNQ1**: The KCNQ1 gene, through its encoded Kv7.1 potassium channel, plays a crucial role in cardiac repolarization; variability in this gene can predispose individuals to drug-induced arrhythmias, notably Long QT Syndrome (LQT). Drugs such as epirubicin and fluorouracil, known to potentially prolong the QT interval, may have pharmacodynamic interactions with KCNQ1, increasing arrhythmia risk, while the interactions of metabolic drugs like metformin and rosiglitazone with KCNQ1 are less clear and might indirectly affect cardiac health.

**UGT2B7**: UGT2B7 is crucial in the metabolism and clearance of various drugs, including opioids like morphine and buprenorphine, antiretrovirals such as zidovudine, antiepileptics like valproic acid, cardiovascular drugs, and NSAIDs among others, influencing their efficacy, side effects, and toxicity. Genetic variability in UGT2B7 can significantly impact the pharmacokinetics and therapeutic outcomes of these drugs, which may require personalized dosing to optimize benefits and minimize adverse reactions.

**CYP4F11**: The enzyme CYP4F11 is involved in the metabolism of drugs such as warfarin, aspirin, and erlotinib, influencing their effectiveness and safety by altering degradation rates, plasma levels, therapeutic efficacy, and the profile of side effects. Variations in the activity of CYP4F11 can affect how these drugs are processed in the body, thereby potentially impacting dosage requirements and risk of adverse effects.

**CACNA1C**: Variations in the CACNA1C gene, which encodes the alpha-1C subunit of L-type calcium channels, significantly affect the pharmacodynamics of several cardiovascular drugs such as verapamil, nifedipine, amlodipine, felodipine, nimodipine, and nitrendipine by altering their efficacy in modulating calcium influx, which is crucial for treating hypertension and cardiac arrhythmias. Additionally, lacidipine and ritodrine interact with these channels, influencing cardiac and smooth muscle function, while drugs like valproic acid, warfarin, citalopram, and atenolol may have indirect interactions through shared signaling pathways or cardiovascular impacts, with gene polymorphisms potentially affecting therapeutic outcomes.

**NOS1AP**: The gene NOS1AP affects cardiac electrophysiology by influencing the QT interval, impacting the effectiveness and risks of drugs like amiodarone and sotalol used in arrhythmia management, due to its role in altering cardiac repolarization intervals. Additionally, variations in NOS1AP may modify the cardiovascular effects and risk profiles of other drugs such as glimepiride, repaglinide, glyburide, glipizide, dolasetron, granisetron, digoxin, and verapamil, though interactions are more complex and deal more with dynamic cardiovascular responses rather than direct enzymatic metabolism.

**CYP4B1**: CYP4B1, which is involved in the metabolism of fatty acids and xenobiotics, may potentially interact with drugs like docetaxel and thalidomide due to their structural similarities to fatty acids. This interaction could alter the pharmacokinetics of these drugs, affecting their efficacy and safety, although direct evidence of this is currently limited.

**CYP2A6**: CYP2A6, an enzyme from the cytochrome P450 superfamily, influences the metabolism of various drugs, impacting their efficacy and toxicity due to genetic variations. It plays a critical role in metabolizing smoking cessation aids like nicotine, cancer treatments such as cyclophosphamide and tegafur, HIV treatment efavirenz, and the glaucoma drug pilocarpine, necessitating dosage adjustments or changes in drug choices to optimize outcomes and minimize side effects.

**IGF2-AS**: The IGF2-AS gene, by modulating IGF2 expression through its antisense RNA, influences the effectiveness and safety of drugs like growth hormone replacements and insulin therapies which target the insulin-like growth factor pathway. Alterations in IGF2-AS can lead to varied responses to these treatments, necessitating adjustments in drug dosages and approaches to maximize efficacy and minimize adverse effects in conditions like growth hormone deficiencies and diabetes.

**XRCC5**: XRCC5, a gene important in DNA repair, influences interactions with drugs like cisplatin, carboplatin, etoposide, and ionizing radiation treatments, which induce DNA breaks, and thus affects cancer treatment outcomes and toxicity based on its variants. Thalidomide might also interact with XRCC5, potentially influencing DNA repair processes indirectly due to its role in cellular responses to DNA damage.

**CYP4X1**: CYP4X1, through its role in the hydroxylation of fatty acids, may indirectly influence the pharmacokinetics of lipid-soluble drugs like fluorouracil and cyclophosphamide, potentially affecting their distribution or clearance due to changes in lipid metabolism pathways. Although direct interactions of CYP4X1 with these drugs are not established, its enzymatic activity in fatty acid metabolism suggests possible effects on how these drugs are processed within the body's lipid environments.

**CYP4F12**: CYP4F12, a cytochrome P450 enzyme, influences the metabolism of drugs that interact with lipid metabolism pathways, including NSAIDs, by affecting processes like hydroxylation of fatty acids. Variants in CYP4F12 could alter the pharmacokinetics of these drugs, potentially impacting their efficacy and safety.

**KCNMA1**: The KCNMA1 gene encodes the BK channel which regulates neuronal and smooth muscle activity, with pharmacogenetic interactions including drugs like quetiapine potentially affecting neuronal excitability indirectly through pharmacodynamic pathways, despite no direct pharmacokinetic interaction. Additionally, drugs such as paxilline and iberiotoxin directly interact with BK channels by inhibiting them, illustrating the impact of BK channel modulation on therapeutic outcomes.

**CYP4A11**: CYP4A11, a gene involved in fatty acid metabolism, has potential pharmacogenetic implications in hypertension treatment, particularly through indirect interactions with potassium-sparing diuretics like spironolactone and amiloride. These interactions are speculated to involve modulation of hormonal pathways or ion transport mechanisms, rather than direct metabolism by the enzyme, affecting fluid and electrolyte balance critical for blood pressure regulation.

**CYP4F3**: CYP4F3, an enzyme integral to the metabolism of leukotriene B4 and drugs like benzphetamine, influences both the pharmacokinetics and pharmacodynamics of these substances. It modifies the metabolic processing of drugs, potentially affecting their efficacy and side effects, and modulates responses to drugs that act on inflammatory pathways by influencing arachidonic acid metabolism. These interactions could significantly impact therapeutic outcomes, especially in individuals with variant forms of the enzyme.

**CYP1B1**: CYP1B1 plays a crucial role in the metabolism of a variety of drugs, notably affecting the efficacy and toxicity of oncological treatments such as cyclophosphamide, docetaxel, doxorubicin, epirubicin, paclitaxel, and fluorouracil, and influencing the activation and effectiveness of pain management drugs like codeine and tramadol. Genetic polymorphisms in CYP1B1 can lead to altered enzyme activity, potentially necessitating dosage adjustments to optimize therapeutic outcomes and minimize side effects.

**CACNB2**: Variants in the CACNB2 gene, which regulates voltage-dependent calcium channels, can significantly impact the effectiveness and metabolism of calcium channel blockers like verapamil, used in treating arrhythmias and hypertension. These genetic variations may affect verapamil's interaction with calcium channels, potentially altering the drug’s ability to stabilize heart rhythms or control blood pressure due to changes in the channels' expression or function.

**SCN5A**: SCN5A, a gene important for cardiac rhythm regulation, influences the interaction with class I antiarrhythmic drugs like lidocaine, flecainide, and quinidine, which block sodium channels it encodes. Variants in SCN5A can modify the effectiveness and safety of these drugs, potentially leading to altered therapeutic outcomes or increased risk of drug-induced arrhythmias, highlighting the importance of genetic consideration in personalized medical treatment for arrhythmias.

**CYP4F8**: CYP4F8 plays a role in the metabolism of fatty acids and leukotriene B4, suggesting that variations in this gene could influence the metabolism and efficacy of dermatological and anti-inflammatory drugs, particularly those like montelukast or zileuton that target leukotriene pathways. The interaction of CYP4F8 with these drugs primarily affects their pharmacokinetics, potentially altering drug effectiveness and safety.

**KCNIP4**: KCNIP4, which modulates Kv4 family voltage-gated potassium channels and thus affects neuronal excitability and firing patterns, could interact with epilepsy drugs like Phenytoin and Carbamazepine that target potassium channels. Although the interactions remain theoretical, changes in KCNIP4 could impact the pharmacodynamics of these drugs, influencing their efficacy or toxicity by altering potassium channel behavior.
